// App-Quantinova.ai

1808 : Loss of BAP1/BRCA1 counteracts spindle assembly checkpoint activation by the anti-mesothelin antibody drug-conjugate anetumab ravtansine

Researchers

Presenter

  • Anita Singh

Principal Investigators

  • Jin-li Luo

  • Sara Busacca

  • Alan Dawson

  • Krishna Kalyan Kolluri

  • Samuel Janes

  • Andrew Fry

  • Anette Sommer

  • Dean Fennell

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Kings College London, London, United Kingdom

  • Bayer, Berlin, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mesothelioma

  • Solid malignancies

Biomarkers

  • BRCA1-associated protein 1

  • Breast cancer type 1 susceptibility protein

  • Renin

  • Apparent diffusion coefficient

Drug/Treatment

  • anetumab ravtansine

  • Vinorelbine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved